A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: The bumetanide and furosemide on lipid profile (BUFUL) clinical study report

Journal of Clinical Pharmacology

Volumn 38, Issue 7, 1998, Pages 630-635

  Van Der Heijden, Marjon ^a   Donders, Servaes H ^a   Cleophas, Ton J ^b   Niemeyer, Menco G ^a   Van Der Meulen, Jan ^b   Bernink, Peter J ^a   De Planque, Ben A ^a   Van Der Wall, Ernst E ^c  

^a MARTINI HOSPITAL   (Netherlands)

^b Merwede Ziekenhuis   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; CHLORTALIDONE; CHOLESTEROL; FUROSEMIDE; LIPID; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031902257     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04470.x     Document Type: Article

References (29)

1. Medical Research Council Working Party: MRC trial of mild hypertension: principal results. Br Med J 1985;291:97-104.
2. Wilhelmsen L, Berglund C, Elmfeld D, Fitzimons T, Holzgreve H, Hosie J: Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-572.
3. Medical Research Council Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
4. Kostis JB, Davis BR, Cutler J, Grimm RH, Berge KG, Cohen JD, et al, for the SHEP Cooperative Reseach Group: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated hypertension. JAMA 1997;278:212-216.
5. Greenbeg B, Brennan PJ, Miall WE: Effects of diuretic and beta-blocker therapy in the Medical Research Council trial. Am J Med 1984;76:45-51.
6. Weidman P, Gerber A, Mordasini R: Effects of antihypertensive therapy on serum lipoproteins. Hypertension 1983;5:III-120-III-131.
7. Gluck Z, Baumgarten G, Weidmann P: Increased ratio between beta-and alpha-lipoproteins during diuretic therapy: an adverse effect. Clin Sci Mol Med 1978;55(Suppl 4):325-328.
8. Stamler R, Stamler J, Gosch FC, Berkson DM, Dyer A, Hershinow P: Initial antihypertensive drug therapy: alpha blocker or diuretic. Interim report of a randomized controlled trial. Am J Med 1986;80:90-93.
9. Boehringer K, Weidmann P, Mordasini R, Schiffl H, Bachmann C, Riesen W: Menopause-dependent plasma lipoprotein alterations in diuretic-treated women. Ann Intern Med 1982;97:206-209.
10. Lind L, Berne C, Pollare T, Lithell H: Metabolic effects of antihypertensive treatment with nifedipine or furosemide: a double-blind, crossover study. J Hum Hypertens 1995;9:137-141.
11. Weidmann P, Bianchetti MG, Mordasini R: Efects of indapamide and various diuretics alone or combined with beta-blockers on serum lipoproteins. Curr Med Res Opin 1983;8(Suppl 3):123-134.
12. Weidmann P, Gerber A: Effects of diuretics on serum lipoproteins. J Cardiovasc Pharmacol 1984;6(Suppl 1):526-528.
13. Bloomgarden ZT, Ginsberg-Fellner F, Rayfield EJ, Bookman J, Brown WV: Elevated hemoglobin A1C and low density lipoprotein cholesterol levels in diuretic-treated diabetic patients. Am J Med 1984;77:823-827.
14. Ames RP: The effects of antihypertensive drugs on serum lipids and lipoproteins. Drugs 1986;32:260-278.
15. Houston MC: New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis. Am Heart J 1989;117: 911-951.
16. Weidmann P, de Courten M, Ferrari P: Effect of diuretics on plasma lipid profile. Eur Heart J 1992;13(Suppl):61-67.
17. Sonnichsen AC von, Richter WO, Schwandt P: Der einfluss von Diuretika auf die Serumlipoproteine. Fortschr Med 1992;110: 625-628.
18. Kasiske BL, Ma JZ, Kalil RSN, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-141.
19. Finnerty FA, Maxwell MH, Lunn J: Long-term effets of furosemide and hydrochlorothiazide in patients with essential hypertension: a two-year comparison of efficacy and safety. Angiology 1977;28:125-133.
20. Van Meyel JJ: Clinical pharmacological studies on loop diuretics. Pharm World Sci 1994;16:29-32.
21. Daensvang PA: Changing Burinex K (bumetanide + potassium) to furosemide/amiloride treatment increases cholesterol and decreases HDL-cholesterol. Curr Ther Res 1991;50(Suppl A): 35-40.
22. Barth JD: Pilot study Nm 25397. Nijmegen, Netherlands: Nijmegen Medical School, 1997.
23. Joint National Committee: The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V). Arch Intern Med 1993;153:154-183.
24. Jones B, Kenward MG: Design and Analysis of Crossover Trials. London: Chapman and Hall, 1989.
25. Collins R, Peto R, MacMahon S, Hebert P, Eberllein KA, Godwin J, et al: Blood pressure, stroke and coronary heart disease. II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335: 827-838.
26. Staessen JA, Fagard R, Thijs L, Cells H, Arabidze GG, Birkenhager WH, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
27. Fink GD: Antihypertensive drugs. In, Brody TM, Larner J, Minneman KP, Neu HC (eds.): Human Pharmacology. New York: Mosby, 1994;159-173.
28. Oates JA: Antihypertensive agents and the drug therapy of hypertension. In, Hardman JG, Limbird LE (eds.): Goodman & Gilman's Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996;781-808.
29. Cleophas TJ: Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities. Br J Clin Pharmacol 1996;41:235-239.